Intra Cellular Therapies reported $143.5M in Operating Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Acadia Pharmaceuticals ACAD:US $ 168.21M 60.27M
ALKERMES ALKS:US 310.68M 5.55M
Aptinyx Inc APTX:US $ 17.1M 2.27M
Biocryst Pharmaceuticals BCRX:US $ 100.25M 374K
Biogen BIIB:US $ 2648.2M 727.1M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Cytokinetics CYTK:US $ 99.84M 18.14M
Esperion Therapeutics ESPR:US $ 71.22M 9.39M
Gilead Sciences GILD:US $ 4231M 2162M
Halozyme Therapeutics HALO:US $ 118.3M 76.7M
Intra Cellular Therapies ITCI:US $ 143.5M 35.84M
JAZZ PHA JAZZ:US $ 847.33M 121.16M
Johnson & Johnson JNJ:US $ 18.18B 616M
Marinus Pharmaceuticals MRNS:US $ 38.56M 7.66M
Minerva Neurosciences NERV:US $ 6.97M 1.02M
Nektar Therapeutics NKTR:US $ 174.42M 33.04M
Neurocrine Biosciences NBIX:US $ 393.5M 86M
Novartis NVS:US 10.86B 895M
Prothena PRTA:US 44.52M 5.42M
Redhill Biopharma RDHL:US 31.47M 11.3M
Supernus Pharmaceuticals SUPN:US $ 158.7M 8.17M
United Therapeutics UTHR:US $ 265.1M 89.5M
Vanda Pharmaceuticals VNDA:US $ 60.93M 6.93M